In Vitro Hemolysis Testing Analysis: Principles, Methods, and Regulatory Compliance for Blood-Contac

In vitro hemolysis testing is a critical biocompatibility study that evaluates the potential of medical devices, biomaterials, and their extracts to damage red blood cells and cause hemoglobin release. Conducted in accordance with ISO 10993-4, ASTM F756, and GB/T 16886.4, this analysis is a mandatory component of biological safety evaluation for blood-contacting products pursuing regulatory registration worldwide. This article provides a comprehensive overview of in vitro hemolysis test principles, sample types, test procedures, calculation methods, acceptance criteria, and practical applications in medical device development.

Technical Overview

Hemolysis refers to the rupture of red blood cell membranes and the subsequent release of hemoglobin into the surrounding plasma or medium. When blood-contacting medical devices or their extractable substances interact with circulating blood, mechanical shear forces, surface chemistry, residual chemicals, or leachable compounds may induce red blood cell destruction, potentially leading to anemia, reduced oxygen transport capacity, thrombosis, and organ dysfunction. The in vitro hemolysis test quantifies this red blood cell damage under controlled laboratory conditions and serves as one of the most fundamental screening assays in biological safety evaluation.

The core principle of the test involves incubating the test sample, or an extract prepared from the sample, with diluted anticoagulated fresh blood at physiological temperature. Following incubation, the mixture is centrifuged to separate intact cells, and the absorbance of the supernatant is measured spectrophotometrically at 545 nm, the characteristic absorption wavelength of free hemoglobin. The hemolysis index is then calculated by comparing the optical density of the test article against positive and negative controls.

The in vitro hemolysis test is primarily governed by the following standards and guidelines:

• ISO 10993-4, Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood, which categorizes hemolysis testing as a key hemocompatibility endpoint.
• ASTM F756, Standard Practice for Assessment of Hemolytic Properties of Materials, which defines the extract-based rabbit blood method and hemolysis index classification.
• GB/T 16886.4, the Chinese national standard harmonized with ISO 10993-4, widely applied for NMPA medical device registration submissions.

Because the assay is rapid, sensitive, and cost-effective compared with in vivo thrombosis models, it is generally performed early in the biocompatibility test sequence for any device with direct or indirect blood contact.

Testing Samples

Direct Blood-Contact Medical Devices

Devices intended for intravascular or intravenous use constitute the largest category of test samples. Typical examples include intravenous catheters, peripheral and central venous cannulas, infusion sets, syringes, stopcocks, transfusion sets, and blood collection tubes. Because these products contact circulating blood directly, hemolysis evaluation is universally required for their regulatory submission.

Extracorporeal Circulation Products

Products used in extracorporeal circuits experience prolonged and high-flow blood contact, making hemocompatibility assessment essential. Representative samples include hemodialyzers, extracorporeal membrane oxygenation (ECMO) components, oxygenators, blood filters, cardiopulmonary bypass tubing kits, apheresis sets, and cell salvage reservoirs.

Implantable Cardiovascular Devices

Long-term implants that remain in contact with blood, such as vascular stents, stent grafts, artificial heart valves, vascular grafts, pacemaker leads, closure devices, and inferior vena cava filters, require hemolysis evaluation as part of the overall ISO 10993-4 blood interaction test strategy, often supplemented with thrombogenicity and complement activation studies.

Raw Materials, Coatings, and Auxiliary Products

Polymeric resins, elastomers, metal alloys, ceramics, hydrophilic coatings, antithrombotic surface treatments, drug coatings, and packaging materials that contact blood-contacting products may be screened using the hemolysis assay during material selection. Additionally, wound dressings, hemostatic agents, dental materials, and pharmaceutical containers are frequently evaluated when blood exposure is anticipated.

Testing Items

The in vitro hemolysis analysis program typically encompasses the following measurable endpoints:

• Hemolysis index (hemolysis rate) calculated from the optical density of the test article supernatant relative to controls.
• Direct contact hemolysis, in which the intact sample physically contacts diluted blood without an intermediate extraction step.
• Indirect contact (extract-based) hemolysis, in which saline or PBS extracts of the sample are incubated with diluted blood.
• Supernatant absorbance measurements at 545 nm for the test article, negative control, and positive control.
• Visual and spectrophotometric confirmation of positive control complete hemolysis and negative control baseline stability.
• Optional supporting endpoints, such as plasma free hemoglobin quantification and morphological observation of erythrocytes, when combined with broader hemocompatibility panels.

Testing Methods

Sample Preparation and Extraction

Samples are cleaned, sterilized if applicable, and cut or arranged according to a standardized extraction ratio, commonly 3 cm² of total surface area per milliliter of extractant for flat materials or 0.1 to 0.2 g of material per milliliter for irregular solids. Physiological saline or phosphate-buffered saline (PBS) is used as the extraction vehicle. Extraction is performed at 37°C for 24 hours under static conditions to simulate physiological leaching of soluble substances.

Blood Preparation

Fresh anticoagulated blood, most commonly obtained from healthy New Zealand white rabbits using anticoagulants such as acid-citrate-dextrose (ACD) or heparin, is collected immediately before testing. The whole blood is diluted with PBS at a defined ratio, typically 1:7 to 1:9, to ensure that the absorbance of the fully hemolyzed positive control falls within the linear detection range of the spectrophotometer.

Incubation and Measurement Procedure

Equal volumes of diluted blood are added to the test extract, the negative control (blank PBS), and the positive control (distilled water or a detergent solution). The tubes are incubated at 37°C for a defined contact period, typically 2 to 3 hours with gentle inversion at intervals to maintain uniform contact. Following incubation, all tubes are centrifuged at approximately 1000 × g to pellet intact cells. The supernatant absorbance is then measured at 545 nm in triplicate.

Calculation and Acceptance Criteria

The hemolysis index is calculated using the following relationship:

Hemolysis index (%) = (OD of test article − OD of negative control) / (OD of positive control − OD of negative control) × 100%.

Interpretation of results generally follows these criteria:

• A hemolysis index of 5% or less is conventionally regarded as non-hemolytic or acceptable for most blood-contacting devices under GB/T 16886.4-based submissions.
• ASTM F756 provides a graded classification in which 0–2% indicates non-hemolytic, 2–5% indicates slightly hemolytic, and values above 5% indicate hemolytic behavior.
• Results exceeding the acceptance threshold trigger investigation of extractable substances, surface treatments, or manufacturing residues, followed by design optimization and retesting.

Test validity requires that the positive control demonstrates near-complete hemolysis, the negative control remains visually clear with absorbance near baseline, and replicate measurements exhibit acceptable precision.

Applications

In vitro hemolysis test data support a wide range of regulatory, developmental, and quality objectives:

• Regulatory registration dossiers submitted to NMPA, FDA, and EU notified bodies under the EU MDR, where ISO 10993-4 and GB/T 16886.4 compliance is expected for blood-contacting devices.
• Material screening and comparative selection during early-stage research and development, enabling rapid identification of hemolytic leachables or aggressive surfaces before tooling investment.
• Design verification for coatings, surface modifications, and drug-device combination products intended to improve hemocompatibility.
• Root cause investigation when hemocompatibility failures or clinical observations of hemolysis arise during post-market surveillance.
• Batch release and periodic quality control testing for extracorporeal circulation consumables in routine manufacturing.
• Scientific publication and standardization research documenting the blood compatibility of novel biomaterials.

Many manufacturers engage accredited third-party laboratories holding ISO/IEC 17025 accreditation to perform hemolysis studies within a comprehensive ISO 10993 biological evaluation report, ensuring data integrity and global regulatory acceptance.

FAQ

When is an in vitro hemolysis test required?

The test is required for any medical device category described as blood-contacting under ISO 10993-4, including circulatory system devices, extracorporeal circuits, and implants exposed to circulating blood. It is also recommended for devices that may transiently contact blood or whose extracts could reach the bloodstream.

What blood source is used in the test?

Fresh rabbit blood diluted with PBS is the most widely used source under ASTM F756 and GB/T 16886.4-based protocols. Fresh human anticoagulated blood may be used when justified, and the dilution ratio is validated to keep the positive control absorbance within the linear spectrophotometric range.

What is the standard acceptance criterion for the hemolysis index?

A hemolysis index of 5% or less is generally accepted as evidence of non-hemolytic behavior in regulatory submissions, while ASTM F756 further differentiates non-hemolytic (0–2%), slightly hemolytic (2–5%), and hemolytic (greater than 5%) classifications.

What is the difference between the direct contact and extract methods?

The extract (indirect) method evaluates hemolytic substances leached from the sample into saline or PBS and is suitable for most devices. The direct contact method places the intact sample in contact with diluted blood, capturing both leachables and surface-induced damage, and is preferred for devices where mechanical or surface effects are the primary concern.

How much sample is needed and how long does testing take?

Typical protocols require sufficient material to achieve the standard extraction ratio, generally several grams or a defined surface area of the final product in its sterilized, ready-to-use condition. The complete workflow, including extraction, incubation, measurement, and reporting, is usually completed within one to two weeks at an accredited laboratory.

What should be done if a sample fails the hemolysis test?

Failures should prompt a systematic review of raw materials, surface treatments, cleaning processes, sterilization residues, and extractable or leachable profiles. After design or process optimization, the hemolysis test is repeated, ideally alongside chemical characterization studies to confirm the corrective action eliminated the hemolytic factor.